Four patients, four countries, four genotypes — and one editing approach the company had previously reported in a single population
One base editor, four patients, four different underlying mutations.
It never touches the mutation itself.
CorrectSequence Therapeutics reported new clinical results in Cell Stem Cell. Its transformer Base Editor therapies CS-101 and CS-206 produced transfusion independence or freedom from vaso-occlusive crises in four patients from Nigeria, Laos, Malaysia and Pakistan, carrying four different genotypes. It is a small, single-arm, sponsor-reported result, and it is the first time the company has reported this editing strategy across this range of genotypes.
What was published
On September 7, 2026, Cell Stem Cell published clinical research from CorrectSequence Therapeutics and collaborating institutions, in a paper titled Clinical base editing for β-hemoglobinopathies across different genetic backgrounds. The therapies are CS-101 and CS-206, both built on the company’s transformer Base Editor, or tBE.
The tBE edits the HBG1/2 promoter region in autologous haematopoietic stem and progenitor cells collected from the patient. That edit reactivates γ-globin expression, raising fetal haemoglobin. It is the same endpoint the Cas9 and Cas12a regimens discussed below are measured on, reached by a different molecular route.
The company had previously reported five Chinese patients with transfusion-dependent β-thalassemia treated with CS-101, all of whom achieved transfusion independence. That earlier work was published in Nature. The new paper adds four patients from outside that population.
The four patients
One had sickle cell disease. Three had transfusion-dependent β-thalassemia. They came from Nigeria, Laos, Malaysia and Pakistan.
The sickle cell patient was a 21-year-old woman from Nigeria who had experienced more than four vaso-occlusive crises in the year before enrolment. Neutrophil engraftment came on day 13 and platelet engraftment on day 21. Total haemoglobin rose from 7.7 g/dL at baseline to 12.9 g/dL at month 3, and stayed above 11 g/dL.
HbF rose from 3.5% to 62.2%. HbS fell from 76.1% to 31.6%. No vaso-occlusive crises through 15.5 months of follow-up.
The three thalassemia patients were aged 3 to 29. Median neutrophil engraftment was 13 days and median platelet engraftment 27 days. Mean total haemoglobin reached 11.6 ± 1.2 g/dL and mean HbF 9.8 g/dL at month 3.
At a median 17.5 months of follow-up, all three had sustained transfusion independence. The company reports no detectable off-target edits and no product-related adverse events across the cohort.
Why four genotypes is the point
The headline result here is not the haemoglobin numbers. It is that the four patients did not share a genotype.
The sickle cell patient carried βˢ/βˢ. The three thalassemia patients carried β⁰/βᴱ, β⁰/β⁰ with a large deletion, and β⁰/β⁰ with a single-nucleotide insertion. Four different underlying mutations, one editing strategy.
That works because of where the edit lands. The tBE does not correct the causative mutation in the β-globin gene. It edits a promoter upstream and switches a second gene back on, which is why the causative mutation can differ from patient to patient without changing the approach.
β-haemoglobinopathies are among the most common monogenic disorders, and their pathogenic mutations vary substantially across populations. Sickle cell disease affects more than 300,000 newborns a year worldwide and transfusion-dependent thalassemia more than 40,000. A therapy validated in one population is not automatically a therapy for that whole global patient count.
Four patients do not settle that question either. What they do is move it from untested to tested-in-a-handful, which is a different conversation with a regulator than the one that existed a week ago.
The comparison with nuclease editing, and how to read it
The company sets its results against Cas9 and Cas12a regimens in sickle cell disease. On its figures, tBE reached neutrophil engraftment at 13 days versus 27 for Cas9 and 23 for Cas12a, and platelet engraftment at 21 days versus 35 and 25. It also reports sustained HbF above 60% of total haemoglobin, against under 50% for the nuclease regimens.
Read those numbers at the strength they were produced. The release compares outcomes from different studies and does not describe a head-to-head trial, so the tBE and nuclease figures do not come from patients randomised against each other. Treat the gap as a difference between datasets until a direct comparison exists.
The mechanistic argument underneath is more durable than the cross-trial numbers. Unlike nucleases, a base editor converts one base without cutting both DNA strands. On the company’s account, that avoids the double-strand-break biology that brings p53 activation, apoptosis, large deletions and chromosomal rearrangements with it.
CorrectSequence adds a dual-guide, lock-and-key design intended to keep the editor inactive until it binds the intended site. That is a design claim about off-target risk, and the four-patient dataset reporting no detectable off-target edits is consistent with it. Consistent with is not the same as demonstrated at scale.
What this means for a CGT program
One editing strategy produced transfusion independence or freedom from vaso-occlusive crises across four different genotypes in four countries. CS-101 and CS-206 have now treated more than 30 patients in total.
More than 30 patients treated to date. All transfusion independent or free of vaso-occlusive crises, on the company’s own account.
The edit targets the HBG1/2 promoter, which is shared across these genotypes, rather than each causative mutation. CS-101 has completed Phase I and is in pivotal trials, with the first patient dosed in October 2023 and the longest transfusion-independent follow-up approaching three years.
GTC analysis: for a programme editing a shared regulatory element rather than a private mutation, genotype diversity in the enrolled population is evidence, not noise. That moves enrolment design out of clinical operations and into the regulatory case.
A sponsor running this class of asset should enrol deliberately across genotypes and ancestries. It should power the analysis to show consistency across them, rather than treat a homogeneous first cohort as the cleaner path to a filing.
GTC analysis: the same logic runs into a CMC and comparability constraint. Multi-country enrolment in an autologous ex vivo product means apheresis at sites with different collection practices.
It also means longer and more variable shipping legs, and a comparability argument that has to hold across all of them.
If you have run an ex vivo HSPC process through this kind of comparability question, CMC and analytical experts get matched to paid consulting work through the GTC Expert Network: join free.
A sponsor may decide to broaden enrolment on the strength of a result like this one. Budget the logistics and comparability work into the same decision. Otherwise the risk moves from the clinic to the supply chain, and the clinical argument outruns the manufacturing one.
One caution worth stating plainly. Everything above rests on a company press release describing the company’s own paper, in a single-arm study of four patients, with no independent replication and no regulatory determination.
That is a normal evidentiary position for a result this fresh. It is not a reason to ignore it, and it is not yet a reason to re-plan a programme around it.
Frequently asked questions
What did CorrectSequence report, and where?
On September 7, 2026, Cell Stem Cell published clinical research from CorrectSequence Therapeutics and collaborating institutions, titled "Clinical base editing for β-hemoglobinopathies across different genetic backgrounds." It reports four patients treated with CS-101 or CS-206, base-editing therapies built on the company’s transformer Base Editor (tBE). One patient had sickle cell disease and three had transfusion-dependent β-thalassemia. All achieved rapid haematopoietic reconstitution, sustained high-level fetal haemoglobin expression, and either complete transfusion independence or freedom from vaso-occlusive crises.
Why does treating patients from four different countries matter?
Because they carried four different genotypes. The sickle cell patient carried βˢ/βˢ, and the three thalassemia patients carried β⁰/βᴱ, β⁰/β⁰ with a large deletion, and β⁰/β⁰ with a single-nucleotide insertion. Pathogenic mutations in β-haemoglobinopathies vary significantly across populations, so a therapy validated in one population does not automatically transfer. The tBE approach edits the HBG1/2 promoter to reactivate γ-globin rather than correcting each causative mutation, which is the mechanistic reason one strategy can span different genotypes.
What were the clinical results?
The sickle cell patient, a 21-year-old woman from Nigeria, achieved neutrophil engraftment on day 13 and platelet engraftment on day 21. Her total haemoglobin rose from 7.7 g/dL to 12.9 g/dL at month 3. HbF rose from 3.5% to 62.2% and HbS fell from 76.1% to 31.6%. She had no vaso-occlusive crises through 15.5 months of follow-up. The three thalassemia patients, aged 3 to 29, reached median neutrophil engraftment at 13 days and median platelet engraftment at 27 days. Mean total haemoglobin was 11.6 g/dL at month 3, with sustained transfusion independence at a median 17.5 months. No off-target edits or product-related adverse events were detected.
Is base editing better than Cas9 or Cas12a editing here?
The company reports faster engraftment and higher fetal haemoglobin for tBE than for Cas9 and Cas12a regimens in sickle cell disease. Those figures come from different studies, and the release does not describe a head-to-head trial in which the approaches were compared directly. Until such a comparison is published, the gap is a difference between datasets rather than a measured difference between treatments. The more durable argument is mechanistic. A base editor converts a single base without creating a double-strand break. On the company’s account, that avoids the p53 activation, apoptosis, large deletions and chromosomal rearrangements associated with nuclease cutting. CorrectSequence also uses a dual-guide, lock-and-key design intended to keep the editor inactive away from its target site. The four-patient dataset is consistent with that design claim but does not establish it at scale.
How far along is this programme?
According to the company, CS-101 and CS-206 have together treated more than 30 patients across China, Africa, Southeast Asia and South Asia. The company describes CS-101 as the first ongoing base-editing therapy candidate to enter clinical development, with its first patient dosed in October 2023. It has completed Phase I and is now being evaluated in pivotal trials. The company states that all Phase I patients have maintained transfusion independence for more than a year, with the longest duration approaching three years.
Sources
- Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds – CorrectSequence Therapeutics press release, PR Newswire, Shanghai, September 8, 2026. Every patient-level figure, engraftment day, haemoglobin value, follow-up duration, genotype, cross-trial comparison and programme-status claim in this article comes from this release. It is a company announcement about the company’s own study, not independent reporting.
- Clinical base editing for β-hemoglobinopathies across different genetic backgrounds – Cell Stem Cell, published online September 7, 2026. The underlying peer-reviewed paper, identified by DOI in the release above. Not independently retrieved for this article; the figures reported here are the ones the company stated in its release, and have not been checked against the paper itself.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.